Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program
Lebwohl M, Korman N, Gooderham M, Gottlieb A, Foley P, Eyerich K, Romanelli M, Strober B, Morita A, Li L, Daamen C, Vaile J, Badaka R, Alió A, Puig L. Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program. SKIN The Journal Of Cutaneous Medicine 2025, 9: s538. DOI: 10.25251/skin.10.supp.538.Peer-Reviewed Original ResearchHistory of malignancyOccurrence of malignancyPsoriasis patientsFollow-upDuration of follow-upBaseline patient demographicsTyrosine kinase 2 inhibitorLong-term extensionYear prior to enrollmentTreatment discontinuationClinical characteristicsPatient demographicsPatient withdrawalAdverse eventsDeucravacitinibMalignancyPatient populationMalignant eventsPatientsPsoriasisPooled populationNMSCTrialsBaselineTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply